fbpx

Looks like you’re in the Netherlands, perhaps you’d like to Switch to Global (EN)

Leader Biomedical Group receives approval to distribute bioresorbable grafts in Switzerland

European Medical Contract Manufacturing BV, a Leader Biomedical Group company, has received regulatory approval from Swissmedic to place its range of eTiss® human allografts for dental and orthopaedic applications on the Swiss market.

Using its proprietary eCOO® Technology, Leader Biomedical is able to produce a range of bioresorbable grafts for the Orthopaedic and Dental markets. The eCOO® Technology platform is a milder alternative to cleaning, sterilising, and impregnating human and animal derived bone and tissue using supercritical carbon dioxide (scCO2) instead of harsh chemicals. Grafts processed with eCOO® Technology exhibit certain bio-molecular and mechanical characteristics, such as slower protein degradation, better cell adhesion, superior tensile strength and torque, which make it ideal for indications requiring a graft with weight bearing and tension-sensitive requirements.

The registration was filed at the request of one of its dental customers, a Swiss company active in regenerative care.